Liens rapides
Catégories
Fiches d'information
Les fiches d'information fournissent des informations supplémentaires sur l'industrie mondiale des protéines plasmatiques thérapeutiques.
Publications et présentations
Discover the main highlights of our industry in our latest publications.
Ressources pour les patients
Explorez les ressources de PPTA pour les patients intéressés par les thérapies aux protéines plasmatiques.
Rapports des parties prenantes
Apprenez-en plus en accédant à la collection de rapports de l'industrie.
Actualités et communiqués de presse
Restez au courant de l'actualité et des événements de l'Association.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Dec 1, 2023
PPTA Statement and Reflection on the Quebec Biovigilance Committee’s 8th Biovigilance Forum
All
PPTA statements
Dec 1, 2023
PPTA Statement and Reflection on the Quebec Biovigilance Committee’s 8th Biovigilance Forum
All
PPTA statements
Nov 8, 2023
Summary of the PPTA/FDA Liaison Meeting (November 8, 2023)
PDMPs — which are derived from human plasma from healthy donors — are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin. Without these treatments, many patients might not survive or would have a substantially diminished quality of life. In addition, plasma-derived medicines are also used in everyday treatment, such as supportive treatment in trauma cases, liver disease, cardiac surgery, and in some cases, pregnancy complications.
All
PPTA statements
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/657b49c161b36be580c14e84_2023%20FDA%20Liaison%20Meeting%20Summary_Website_FINAL.pdf
Nov 8, 2023
Summary of the PPTA/FDA Liaison Meeting (November 8, 2023)
PDMPs — which are derived from human plasma from healthy donors — are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin. Without these treatments, many patients might not survive or would have a substantially diminished quality of life. In addition, plasma-derived medicines are also used in everyday treatment, such as supportive treatment in trauma cases, liver disease, cardiac surgery, and in some cases, pregnancy complications.
All
PPTA statements
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/657b49c161b36be580c14e84_2023%20FDA%20Liaison%20Meeting%20Summary_Website_FINAL.pdf
Aucun résultat n'a été trouvé